NDANASALSPRAY, METEREDPriority Review
Approved
Jul 2023
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
RIVIVE (naloxone hydrochloride) by R-Pharm US is clinical pharmacology complete or partial reversal of opioid depression naloxone hydrochloride prevents or reverses the effects of opioids including respiratory depression, sedation, and hypotension. First approved in 2023.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RIVIVE is a nasal spray formulation of naloxone hydrochloride, a pure opioid antagonist approved by FDA in July 2023. It rapidly reverses opioid overdose by competing for opioid receptors (μ, κ, σ) in the central nervous system, with onset of action within 2 minutes. This product addresses the public health emergency of opioid overdose deaths through an accessible, non-injection route.
Growth5.9 years to LOE
Early-stage branded naloxone in growth phase with no direct patent competitors suggests opportunity for market education and formulary expansion teams.
Mechanism of Action
CLINICAL PHARMACOLOGY Complete or Partial Reversal of Opioid Depression Naloxone hydrochloride prevents or reverses the effects of opioids including respiratory depression, sedation, and hypotension. Also, naloxone hydrochloride can reverse the psychotomimetic and dysphoric effects of…
Worked on RIVIVE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.